Two New Embargoed Press Releases

Two new embargoed Neurology® press releases

View in browser
25-Banner-AAN-800x100

Press Releases

25-Graphic-AAN-Pine

News from NEUROLOGY®, Wednesday, July 16, 2025

EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, WEDNESDAY, JULY 16, 2025

Do race and ethnicity play a role in a person’s risk of peripheral neuropathy?

Peripheral Neuropathy 356x192

Shutterstock

MINNEAPOLIS — Hispanic people have an increased risk of peripheral neuropathy compared to white people that cannot be explained by many health, lifestyle and social risk factors, according to a study published July 16, 2025, in Neurology®, the medical journal of the American Academy of Neurology.

 

Peripheral neuropathy is nerve damage that causes burning, tingling, pain and numbness in the feet and hands. It can be debilitating and may eventually lead to falls, infection and even amputation. One of the most common causes of neuropathy is diabetes due to high levels of blood sugar that can damage the nerves. Other causes include diseases like arthritis and lupus, as well as injuries and infections.


“In the United States, there is a higher prevalence of peripheral neuropathy among Hispanic and Black people than white people, and the underlying factors driving these differences are not well defined,” said study author Evan Lee Reynolds, PhD, of Michigan State University in East Lansing. “Race and ethnicity are social constructs without a biological basis and may be proxy, a substitute or indicator, for hard-to-measure risk factors. We looked at a wide range of known risk factors, including health, lifestyle and social factors, and found that Hispanic people still had a higher risk of neuropathy even after those risk factors were considered.”


The study involved 8,014 people, of whom 55% were non-Hispanic white, 24% Hispanic, 18% non-Hispanic Black and 3% of another race or ethnicity. They had an average age of 61 and 13% had peripheral neuropathy. 


A survey was used to identify risk factors for neuropathy. Risk factors included: age and sex; health factors like waist circumference, blood pressure, blood sugar and cholesterol levels; lifestyle factors like physical activity and diet; and social factors including food security, household income and health insurance.


People with neuropathy were older, had lower “good” cholesterol and higher systolic blood pressure. In addition, 25% had diabetes compared to 16% of those without neuropathy. On average, they had a larger waist circumference, ate a lower percentage of healthy fats and were less likely to have completed moderate to vigorous physical activity within the last month compared to those without neuropathy. Also, 40% had a total annual household income of $20,000 or less compared to 32% of people without neuropathy. 


After adjusting for only age and sex, researchers found Hispanic people and Black people had a higher odds of peripheral neuropathy compared to white people.


However, after adjusting for the additional health, lifestyle and social risk factors, Hispanic people had a 32% increased odds of peripheral neuropathy when compared to white people, while Black people had a similar odds as white people.


Researchers found social factors increased the odds of neuropathy, particularly for Hispanic people. Being uninsured increased their odds by 56% and having food insecurity by 48%.


“After comprehensively adjusting for known risk factors, we found that Black people had similar odds of neuropathy compared to white people, whereas Hispanic people continued to be at an increased likelihood of having neuropathy,” said Reynolds. “Therefore, it is likely that unknown social risk factors exist for this population. Identifying additional risk factors for Hispanic people should be the focus of future studies.” 


A limitation of the study was that factors such as diet and exercise were reported by participants and they may not have recalled all information accurately.

 

Discover more about peripheral neuropathy at BrainandLife.org, from the American Academy of Neurology. This resource also offers a magazine, podcast, and books that connect patients, caregivers and anyone interested in brain health with the most trusted information, straight from the world’s leading experts in brain health. Follow Brain & Life® on Facebook, X, and Instagram.

 

The American Academy of Neurology is the leading voice in brain health. As the world’s largest association of neurologists and neuroscience professionals with more than 40,000 members, the AAN provides access to the latest news, science and research affecting neurology for patients, caregivers, physicians and professionals alike. The AAN’s mission is to enhance member career fulfillment and promote brain health for all. A neurologist is a doctor who specializes in the diagnosis, care and treatment of brain, spinal cord and nervous system diseases such as Alzheimer's disease, stroke, concussion, epilepsy, Parkinson's disease, multiple sclerosis, headache and migraine.

 

Explore the latest in neurological disease and brain health, from the minds at the AAN at AAN.com or find us on Facebook, X, Instagram, LinkedIn, and YouTube.

EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, WEDNESDAY, JULY 16, 2025

During pregnancy, are newer antiseizure medications safer than older drugs?

Pregnancy 356x192

Shutterstock

MINNEAPOLIS — A new study that examined older and newer medications to treat seizures has found that using some medications during pregnancy is linked to an increased risk of malformations at birth, or birth defects. The study is published July 16, 2025, in Neurology®, the medical journal of the American Academy of Neurology.

 

“Seizures can lead to falls and other complications during pregnancy, so seizure control for those with epilepsy is crucial to protect the health of both the mother and child,” said study author Sonia Hernandez-Diaz, MD, DrPH, of Harvard T.H. Chan School of Public Health in Boston, Massachusetts. “While some older drugs are known to increase the risk of major malformations, less is known about the safety of newer ‘second generation’ medications. Our study looked at a number of drugs and provides valuable information for health care providers and people who may become pregnant to make more informed decisions about the use of these medications during pregnancy.” 


For the study, researchers looked at 7,311 women who were taking an antiseizure medication during the first trimester of pregnancy. They were compared to 1,311 women who did not take antiseizure medications.


Participants completed phone interviews at the start of the study, at seven months pregnant, and within three months after delivery. 


Researchers confirmed birth defects through medical records. These included cleft lip, larger-than-normal holes in the heart, neural tube defects where the spinal cord does not develop properly such as spina bifida, missing or underdeveloped limbs and other issues where parts of the body did not form correctly. 


They then looked at the risk of these birth defects among infants exposed to specific antiseizure medications taken during the first trimester of pregnancy and compared them to infants exposed to lamotrigine, an antiseizure medication used as the reference group.


Researchers found that the risk of major birth defects varied among medications. Valproate posed the highest risk, with major birth defects occurring in 9% of infants exposed. Phenobarbital followed at 6%. Among newer drugs, birth defects occurred in 5% of those exposed to topiramate, while the group exposed to lamotrigine had malformations in 2% of births.


When compared to those who took lamotrigine, those who took valproate had more than five times the risk of birth defects, those who took phenobarbital had nearly three times the risk, and those taking topiramate had over twice the risk.


"Our results confirm that using valproate, phenobarbital or topiramate during early pregnancy is linked to a higher chance of major birth defects in the infants when compared to lamotrigine,” Hernandez-Diaz said. “On the other hand, our results did not show an increased risk with medications like levetiracetam, oxcarbazepine, gabapentin and zonisamide. For lacosamide and pregabalin, the data wasn’t clear enough to make solid conclusions, so more research is needed."


A limitation of the study was that participants were enrolled months after conception and in most cases early losses of pregnancy were not assessed for malformations, so the number of malformations overall may have been underestimated. 

 

Discover more about epilepsy at BrainandLife.org, from the American Academy of Neurology. This resource also offers a magazine, podcast, and books that connect patients, caregivers and anyone interested in brain health with the most trusted information, straight from the world’s leading experts in brain health. Follow Brain & Life® on Facebook, X and Instagram.

 

The American Academy of Neurology is the leading voice in brain health. As the world’s largest association of neurologists and neuroscience professionals with more than 40,000 members, the AAN provides access to the latest news, science and research affecting neurology for patients, caregivers, physicians and professionals alike. The AAN’s mission is to enhance member career fulfillment and promote brain health for all. A neurologist is a doctor who specializes in the diagnosis, care and treatment of brain, spinal cord and nervous system diseases such as Alzheimer's disease, stroke, concussion, epilepsy, Parkinson's disease, multiple sclerosis, headache and migraine.

 

Explore the latest in neurological disease and brain health from the minds at the AAN at AAN.com or find us on Facebook, X, Instagram, LinkedIn and YouTube.

View Additional AAN Press Releases

Listen to Weekly Neurology® Podcast
 
Sign up for Weekly Neurology® News Alerts

 

 

Notes:

  • Embargoed copies of the studies are available by contacting Renee Tessman at rtessman@aan.com or emailing media@aan.com.
  • For the embargoed study on peripheral neuropathy:
    • Advance interviews with the authors are available by contacting Emily Linnert at wagnerem@msu.edu
    • Advance URL for the embargoed study is https://n.neurology.org/lookup/doi/10.1212/WNL.0000000000213851 (available after embargo lifts)
    • Advance URL for the corresponding editorial is https://n.neurology.org/lookup/doi/10.1212/WNL.0000000000213968 (available after embargo lifts)
  • For the embargoed study on antiseizure medications:
    • Advance interviews with the authors are available by contacting Maya Brownstein at mbrownstein@hsph.harvard.edu
    • Advance URL for the embargoed study is https://n.neurology.org/lookup/doi/10.1212/WNL.0000000000213786 (available after embargo lifts)
    • Advance URL for the corresponding editorial is https://n.neurology.org/lookup/doi/10.1212/WNL.0000000000213959 (available after embargo lifts)
  • Need an independent expert for your story? Contact the AAN to arrange interviews with experts on neurological diseases

Information in AAN press releases is protected by copyright and Neurology® attribution is required

Renee Tessman

Senior Media and Public Relations Manager
American Academy of Neurology
Ph: (612) 928-6137   Mobile: (612) 240-2531
rtessman@aan.com | www.aan.com

 

Michelle Uher
Director, Communications and Public Relations
American Academy of Neurology
Ph: (612) 928-6120
muher@aan.com | www.aan.com

AAN.com | Contact Us

 

This email was sent by: American Academy of Neurology

201 Chicago Avenue, Minneapolis,MN, 55415

(800) 879-1960

 

Please visit AAN.com to read the AAN’s revised Privacy Policy and Terms of Use.

 

If you prefer not to receive these types of emails, please unsubscribe or update your communication preferences.

25-Logo-AAN-Footer-150x76
25-Footer-Logo-Facebook-50x50
25-Footer-Logo-X-50x50
25-Footer-Logo-Instagram-50x50
25-Footer-Logo-LinkedIn-50x50
25-Footer-Logo-YouTube-50x50

©2025 American Academy of Neurology - All Rights Reserved